Safety Study of AMG 228 to Treat Solid Tumors



Status:Terminated
Conditions:Lung Cancer, Colorectal Cancer, Skin Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/14/2017
Start Date:April 2015
End Date:December 2016

Use our guide to learn which trials are right for you!

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity,
and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.


Inclusion Criteria:

- Subject must have a pathologically documented, definitively diagnosed, advanced solid
tumor

- Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria:

- Active autoimmune disease, history of autoimmune disease

- Treatment with immune modulators including

- Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors

- Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or
investigational agent) within 28 days

- Major surgery within 28 days of study day 1
We found this trial at
4
sites
?
mi
from
Parkville,
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials